CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake
Rhea-AI Filing Summary
CorMedix Inc. amendment reports that SHAIBATALHAMD AYMEN ABDALKADER beneficially owns 4,618,511 shares of Common Stock, representing 5.89% of the class, with sole voting and sole dispositive power over those shares. The filing is signed and dated 06/12/2026 as Amendment No. 5.
Positive
- None.
Negative
- None.
Key Figures
Amendment date: 06/12/2026
Shares beneficially owned: 4,618,511 shares
Percent of class: 5.89%
3 metrics
Amendment date
06/12/2026
Signed date on Amendment No. 5
Shares beneficially owned
4,618,511 shares
Amount reported in Item 4(a)
Percent of class
5.89%
Percent of common stock reported in Item 4(b)
Key Terms
Schedule 13G/A, Beneficially owned, Sole power to vote
3 terms
Schedule 13G/A regulatory
"Amendment No. 5 CorMedix Inc. COMMON STOCK"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially owned financial
"Item 4. Ownership (a) Amount beneficially owned: 4,618,511"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole power to vote regulatory
"Number of shares as to which the person has (i) Sole power to vote: 4,618,511"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the CRMD Schedule 13G/A amendment disclose?
It discloses 4,618,511 shares beneficially owned, equal to 5.89% of the class. The filer reports sole voting and sole dispositive power over those shares and signed the amendment on 06/12/2026.
Who filed the CRMD ownership amendment and where is the filer located?
SHAIBATALHAMD AYMEN ABDALKADER filed the amendment. The filer lists a residence/business address in Riyadh, Saudi Arabia at the address shown in the filing.
What class and CUSIP are reported in the CRMD Schedule 13G/A amendment?
The filing reports Common Stock, par value $0.001 per share with CUSIP 21900C308. These identifiers appear on the cover page of the amendment.
What percentage of CorMedix outstanding stock does the filer report owning (CRMD)?
The filer reports ownership equal to 5.89% of the common stock class. That percentage is provided in Item 4(b) alongside the exact share count of 4,618,511.